IVF Sector Losing $450B, 95% of Patients Globally with Current Bottleneck
With demand for in-vitro fertilization (IVF) projected to reach 6.5 million annual cycles by 2035, the current model—dependent on manual lab processes—is inadequate to meet global needs. The existing IVF landscape is constrained by high costs, a severe shortage of embryologists, and inconsistent lab results, limiting access to treatment for the 95% of infertility patients worldwide who go untreated.
Stanford University reports that a single IVF cycle in the United States can cost as much as $30,000, and startup fertility labs require an initial investment of $4 million. Furthermore, existing fertility centers often struggle with escalating operational expenses and workforce shortages, leaving industry stakeholders searching for scalable solutions.
43,000 More Embryologists Required to Meet Demand
To meet the anticipated 2035 demand with current methods, the industry would require more than 50 million intracytoplasmic sperm injections (ICSIs), 43,000 additional embryologists, and the construction of 4,000 new fertility labs. The numbers make clear that manual processes cannot scale to match the market’s growth trajectory. In contrast, an AI-driven automated IVF lab can process 2,000 cycles per year, dramatically increasing accessibility and efficiency.
The automation of the IVF lab will expand access and move the industry from $34 billion a year to nearly half a trillion dollars annually, according to industry experts, a growth potential for embryologists, doctors, clinicians, and business people alike. This shift not only stands to improve patient outcomes but also presents a lucrative opportunity for investors looking to capitalize on the next major wave of medical automation.
The Future of IVF Is Here—Fully Automated, AI-Powered, and Game-Changing
Meet AURA by Conceivable Life Sciences—the first robotics-driven IVF lab designed to revolutionize fertility care.
AI & Robotics: Precision-driven automation for every step of the IVF process.
Scalability & Efficiency: Higher throughput, lower costs, and consistent results.
Accuracy: Minimize human error and optimize embryo outcomes..
Accessible & Innovative: A bold leap toward the future of fertility care.
Be among the first to see what’s possible. Visit Conceivable Life Sciences today
$40 Million Bet on IVF Automation
As other areas of medicine have embraced automation—ranging from diagnostics to robotic-assisted surgery—IVF remains an exception. The prevailing skepticism that embryology cannot be automated has slowed investment, despite clear inefficiencies. However, the industry is beginning to shift. The biotech company Conceivable Life Sciences has built AURA, an AI-powered automated lab that aims to replace the artisanal nature of IVF with machine vision, robotics, data-driven precision, and advanced optics.
Conceivable’s early trials of automated embryology systems have demonstrated success. AURA’s prototype instruments have led to 21 pregnancies and so far the birth of 12 healthy babies, with the balance expected in coming weeks. These early indications demonstrate that Conceivable’s lab performance is on par with top-tier fertility centers. While these results signal a major breakthrough, full-scale commercialization will require substantial investment to refine processes and build the necessary infrastructure.
Investors Flock to IVF Lab Automation
While investors have been interested in the IVF space, many have wondered how they could scale the return of their investments. Today, companies focused on the IVF lab—the most critical component of the process—are beginning to attract serious investment. Conceivable raised $40 million to develop its automated lab to improve consistency, lower costs, and expand access to treatment.
“There are significant tailwinds pushing IVF in the United States alone,” says Conceivable Chairman and co-founder Joshua Abram. “There is the Presidential Executive Order, a new government mandate that offers 2 million federal employees and their families IVF access, and California’s law requiring IVF coverage for 9 million people. These milestones and the increasing demand for IVF will no doubt boost considerable investment.”
Full implementation at scale will definitely require continued investment in both infrastructure and clinical validation. As investors increasingly recognize the potential of automation in IVF, the shift toward lab-focused solutions may define the next phase of growth for the fertility industry.
The Future of IVF Is Here—Fully Automated, AI-Powered, and Game-Changing
Meet AURA by Conceivable Life Sciences—the first robotics-driven IVF lab designed to revolutionize fertility care.
AI & Robotics: Precision-driven automation for every step of the IVF process.
Scalability & Efficiency: Higher throughput, lower costs, and consistent results.
Accuracy: Minimize human error and optimize embryo outcomes..
Accessible & Innovative: A bold leap toward the future of fertility care.
Be among the first to see what’s possible. Visit Conceivable Life Sciences today